TRANSFORM Trial: Clinical Perspectives in Liso-Cel CAR T-Cell Therapy for Second-Line R/R LBCL

TRANSFORM Trial: Clinical Perspectives in Liso-Cel CAR T-Cell Therapy for Second-Line R/R LBCL

An expert discusses that while the liso-cel trial did not show a statistically significant overall survival benefit—likely due to its small sample size and crossover design—it still demonstrated durable responses with a favorable safety profile, offering a valuable, lower-toxicity CAR T option for patients with relapsed or refractory large B-cell lymphoma, particularly those less suited for more aggressive therapies like axi-cel.